Summary

Global anti-venom market is expected to reach a value of US$ 1.95 Billion by 2032, with a projected CAGR of 6.46% between 2024 and 2032. The market was valued at US$ 1.11 Billion in 2023.

Anti-venoms consist of antibodies used to treat venomous stings or bites. The growing prevalence of snake and other animal bites, such as fish stings, drives the anti-venom market.The global market for anti-venom is expected to grow due to increasing investment in developing new drugs and technological innovation in treating venomous bites. The growing incidence of snakebites worldwide is another major factor contributing to market growth. According to the World Health Organization (WHO), around 5.4 million people are bitten by snakes a year, resulting in a high demand for anti-venoms. However, the production of anti-venoms faces regulatory challenges in several countries.


Antivenom Market Data and Statistics

• The WHO has launched a strategy to prevent and control snakebite envenoming, a tropical disease affecting millions annually.
• Snakebites are a significant issue worldwide. In Asia, about 2 million individuals suffer from snakebites each year, while in Africa, an estimated 435,000 to 580,000 people require treatment for snakebites annually.
• India alone has 2.8 million snakebite cases, with 46,900 deaths every year.
• A study from the National Center for Biotechnology Information (NCBI) found that a snakebite treatment ward in a Bangladesh tertiary hospital experienced a 25% decrease in overall snakebite hospital admissions in 2020 compared to previous years.
• Ten laboratories in Latin America, including Instituto Nacional de Salud and Instituto Butantan, have observed a decline in snake antivenom production in 2021.
• According to Centers for Medicare & Medicaid Services (CMS), National Health Expenditures (NHE) in the US are projected to reach USD 6,192.5 Billion in 2028 with an average annual percent change of 5.2%.
• The per capita expenditure is estimated to touch USD 17,611 by 2028, implying that this growth in NHE is expected to create lucrative business opportunities.


United States Anti Venom Market

The anti venom market in the U.S. is expected to have significant growth due to the country's high occurrence of snake bites. The market's expansion is expected to be driven by announcements from considerable market players, such as the Fast Track designation granted by the US FDA to Ophirex'sdarapladib-methyl for the treatment of snakebite, and the approval received by Rare Disease Therapeutics, Inc. for ANAVIP. ANAVIP is approved for managing adult and pediatric patients with pit viper envenomation in the United States of America, and these announcements are expected to contribute to the market's growth.


India Anti Venom Market

India is home to almost 275 species of snakes, out of which only 60 are venomous and considered medically relevant, with four having significant mortality and morbidity. These four venomous snakes are collectively called the "Big Four." Anti-venom is a biological product that detoxifies the poisoning of venomous bites. Venomous bites can result in various clinical conditions, and it is estimated that around 40,000-80,000 people die in Asia, mainly in India, from snakebites annually. Antivenom products have been developed to counter the poisonous effects of venomous bites, including vaccines and hyperimmune sera.


Global Anti Venom Market Company Analysis

The companies that make up the global anti-venom market include Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Merck & Co. Inc., Merck KGaA, Pfizer Inc., and Haffkine Bio-Pharmaceutical Corporation Limited.


Global Anti Venom Market Company News

In July 2022, the AVRDC foundation was laid at IBAB, Bengaluru Helix Biotech Park, Electronics City, to boost antivenom production.
In April 2022, Brazil and the government of Myanmar signed a complementary agreement to improve the quality and performance of anti venom serum produced in Myanmar. The project is "Improving methodologies and techniques for the production of anti venom serum in Myanmar—phase II: anti venom quality."
BSV and IISc collaborated in August 2022 to develop antivenom for snakebites in India, addressing the unique challenges specific to the region.
Ophirex, Inc. received Fast Track Designation from the U.S. FDA in March 2022 for darapladib-methyl, a treatment for snakebite. The FDA recognized the drug's potential benefits and the need to bring it to market efficiently.
Rare Disease Therapeutics, Inc. expanded FDA approval for the ANAVIP antivenom to treat North American Pit Viper Envenomation in April 2021, indicating progress in developing effective snakebite therapies.


Type – Global Anti-Venom Market breakup in 2 viewpoints:

1. Polyvalent Anti-Venom
2. Monovalent Anti-Venom


Animal Type – Global Anti-Venom Market breakup in 4 viewpoints:

1. WheatSnake
2. Scorpion
3. Spider
4. Others


End-User – Global Anti-Venom Market breakup in 4 viewpoints:

1. WheatClinics
2. Hospitals
3. Ambulatory Surgical Centers
4. Others


Country – Global Anti-Venom Market breakup of 25 Countries:

1. North America

1.1 United States
1.2 Canada

2. Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey

3. Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4. Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5. Middle East & Africa

5.1 Saudi Arabia
5.2 UAE
5.3 South Africa


All the Key players have been covered from 3 Viewpoints:

• Overview
• Recent Development
• Revenue Analysis


Company Analysis:

1. Bharat Serums and Vaccines Limited (BSV)
2. Boehringer Ingelheim International GmbH
3. Boston Scientific Corporation
4. CSL Limited
5. Merck & Co. Inc.
6. Merck KGaA
7. Pfizer Inc.
8. Haffkine Bio-Pharmaceutical Corporation Limited

ページTOPに戻る

Table of Contents

1. Introduction

2. Research& Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers
4.2 Challenges


5. Global Anti-Venom Market

6. Market Share – Global Anti-Venom Analysis

6.1 Type
6.2 Animal Type
6.3 End Users
6.4 Country


7. Type – Global Anti-Venom Market

7.1 Polyvalent Anti-Venom
7.2 Monovalent Anti-Venom


8. Animal Type – Global Anti-Venom Market

8.1 Snake
8.2 Scorpion
8.3 Spider
8.4 Others


9. End Users – Global Anti-Venom Market

9.1 Clinics
9.2 Hospitals
9.3 Ambulatory Surgical Centers
9.4 Others


10. Country – Global Anti-Venom Market

10.1 North America

10.1.1 United States
10.1.2 Canada

10.2 Europe

10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey

10.3 Asia Pacific

10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand

10.4 Latin America

10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina

10.5 Middle East & Africa

10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa


11. Porter’s Five Analysis – Global Anti-Venom Market

11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes


12. SWOT Analysis – Global Anti-Venom Market

12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat


13. Key Players

13.1 Bharat Serums and Vaccines Limited (BSV)

13.1.1 Overview
13.1.2 Recent Development
13.1.3 Revenue

13.2 Boehringer Ingelheim International GmbH

13.2.1 Overview
13.2.2 Recent Development
13.2.3 Revenue

13.3 Boston Scientific Corporation

13.3.1 Overview
13.3.2 Recent Development
13.3.3 Revenue

13.4 CSL Limited

13.4.1 Overview
13.4.2 Recent Development
13.4.3 Revenue

13.5 Merck & Co. Inc.

13.5.1 Overview
13.5.2 Recent Development
13.5.3 Revenue

13.6 Merck KGaA

13.6.1 Overview
13.6.2 Recent Development
13.6.3 Revenue

13.7 Pfizer Inc.

13.7.1 Overview
13.7.2 Recent Development
13.7.3 Revenue

13.8 Haffkine Bio-Pharmaceutical Corporation Limited

13.8.1 Overview
13.8.2 Recent Development

ページTOPに戻る

List of Tables/Graphs

Table-01: Global – Anti-Venom Market Share by Type (Percent), 2019 – 2023
Table-02: Global – Forecast for Anti-Venom Market Share by Type (Percent), 2024 – 2032
Table-03: Global – Anti-Venom Market Share by Animal Type (Percent), 2019 – 2023
Table-04: Global – Forecast for Anti-Venom Market Share by Animal Type (Percent), 2024 – 2032
Table-05: Global – Anti-Venom Market Share by End User (Percent), 2019 – 2023
Table-06: Global – Forecast for Anti-Venom Market Share by End User (Percent), 2024 – 2032
Table-07: Global – Anti-Venom Market Share by Countries (Percent), 2019 – 2023
Table-08: Global – Forecast for Anti-Venom Market Share by Countries (Percent), 2024 – 2032